Olanzapine, Samidorphan Dual Therapy Well Tolerated in Schizophrenia
Researchers report on the 52-week extension of the ENLIGHTEN-2 study that assessed the long-term safety and efficacy of treatment schizophrenia with olanzapine and samidorphan.
Researchers report on the 52-week extension of the ENLIGHTEN-2 study that assessed the long-term safety and efficacy of treatment schizophrenia with olanzapine and samidorphan.
Researchers conducted a study to investigate the bidirectional nature of the relationship between obesity and depression.
Extrapyramidal symptoms that developed in patients with schizophrenia after initiation of treatment with atypical antipsychotic agents were associated with increased healthcare resources and costs.
Research was conducted to assess the impact of initiation of treatment with second-generation antipsychotics and treatment interruptions on weight gain in patients with schizophrenia and bipolar 1 disorder.
Overall, 1.71% of individuals with a first lifetime diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified die by suicide.
Patients with schizophrenia or a mood disorder who switched antipsychotic treatment had an increased likelihood for relapse, healthcare resource utilization, and extrapyramidal symptoms.
Nutrient supplements had good safety profiles, no known contraindications with psychiatric medications.
Researchers found data that showed, after a 10-year period, a slight decline for the intelligence quotient of patients with schizophrenia.
Individuals with pediatric-onset bipolar disorder fare better than individuals diagnosed at a later age with the disorder, and bipolar disorder in general is associated with better outcomes than schizophrenia.
Findings showed a higher incidence of hyperglycemic episodes in patients with diabetes and comorbid schizophrenia than in those without schizophrenia.